Switching from Wegovy® to Foundayo®: What to know before you switch

If you’re taking the Wegovy® pill and wondering whether Foundayo® might be a better fit, you’re probably weighing a few important tradeoffs. The confusion is real because while both are once-daily oral GLP-1 medications approved for weight loss, they work a little differently. Those differences can affect everything from your daily routine to the amount of weight you might lose.

Although both medications activate the GLP-1 receptor, they use different active ingredients. Wegovy® contains semaglutide, a peptide that has to be paired with an absorption enhancer so it can be absorbed through the stomach. Because of that, the Wegovy® pill must be taken first thing in the morning on an empty stomach with a small sip of water, followed by a 30-minute wait before eating, drinking, or taking other medications.

Foundayo® contains orforglipron, a non-peptide GLP-1 medication. As a non-peptide, it doesn’t require an absorption enhancer, so it can be taken with or without food and at any time of day. For many people, that added flexibility makes it easier to fit treatment into everyday life.

Convenience, however, isn’t the only consideration. The two medications produced different average weight-loss results in their clinical trials, and they also have some differences in dosing, side effects, and how the transition is typically managed. Because there haven’t been head-to-head studies of people switching from Wegovy® pill to Foundayo®, it’s helpful to understand what we know—and what we don’t.

Here’s what to expect if you’re thinking about making the switch, including how the transition is usually handled, what current research suggests about weight loss after changing medications, and how the side effects compare.

How Foundayo® and Wegovy® differ and why switching requires guidance

Switching from Wegovy® to Foundayo® could be for a few reasons: a change in insurance, a side effect that’s not resolving, or wanting a pill that fits into daily life more easily. Here’s a look at why people might switch from the Wegovy® pill to Foundayo®.

Changes in insurance coverage

Insurance coverage for weight-loss medications isn’t static. Health plans regularly update the list of medications they cover (called a formulary), and those changes can happen from one year to the next—or even during the same plan year. A medication that was covered last year may move to a higher copay tier, require prior authorization or step therapy, or lose coverage altogether, while a similar medication remains covered.

That’s one reason someone might switch from the Wegovy® pill to Foundayo®. Even though both medications treat weight loss, your insurance company may choose to cover one but not the other based on its contracts and negotiations with each drug manufacturer.

If you’re paying cash without insurance, the picture is different. Both manufacturers currently offer self-pay programs with comparable pricing. Through LillyDirect, Foundayo® starts at $149 per month for the introductory dose, while NovoCare’s self-pay program offers the Wegovy® pill starting at $149 per month for the introductory dose. As doses increase, monthly costs rise for both medications, so the overall difference in cash price may be smaller than many people expect.

Read more: 

• What is Foundayo®?
• What is the Wegovy pill? 

Side effect differences

The Wegovy® pill and Foundayo® have similar side-effect profiles because they both work by activating the GLP-1 receptor. The most common side effects include nausea, vomiting, diarrhea, and constipation, especially while you’re increasing your dose.

Both medications are started at a low dose and gradually increased over several months to help your body adjust and reduce gastrointestinal side effects. While the overall side-effect patterns are similar, the rates of individual symptoms differ somewhat between the medications.

Most importantly, there’s no way to predict exactly how you’ll respond. Some people tolerate one medication better than the other, even though they’re in the same drug class. If one medication causes fewer side effects or is easier to take consistently, it may end up being the better long-term option for you—even if average results in clinical trials differ.

Different than expected weight loss

For some people, switching drugs is about getting a stronger result. This is one switch where that’s usually not the case: at their respective maximum doses, Foundayo® is associated with roughly 12% average weight loss, compared with about 14% for the Wegovy® pill. People switching to Foundayo® are typically doing so for cost, coverage, or convenience—not for added weight loss. 

Medication	Maximum dose	Average weight loss
Wegovy® pill (semaglutide)	25 mg	14%
Foundayo® (orforglipron)	17.2 mg	12%

These numbers come from separate trials, not head-to-head studies, so treat them as general trends rather than a guaranteed outcome for any one person. They also don’t capture the whole picture. For some people, a medication with slightly lower average weight loss in clinical trials may still be the better choice if it’s one they can tolerate and take consistently.

Switching from Wegovy® to Foundayo® dosage: How does the transition work?

Although the Wegovy® pill and Foundayo® are both oral GLP-1 medications, they aren’t dosed the same way, and there isn’t an FDA-approved conversion chart for switching between them. Instead of matching your previous Wegovy® dose milligram for milligram, you will start at 0.8 mg, the recommended intro dose for Foundayo. 

Like Wegovy®, Foundayo® is started at a low dose and increased gradually to help reduce gastrointestinal side effects. 

Here’s how the dosing schedules compare:

Medication	Starting dose	How it increases	Maximum dose
Wegovy® pill (semaglutide)	1.5 mg once daily	Earliest every 30 days: 4 mg → 9 mg → 25 mg	25 mg
Foundayo® (orforglipron)	0.8 mg once daily	Earliest every 30 days: 2.5 mg → 5.5 mg → 9 mg → 14.5 mg or 17.2 mg	17.2 mg

Is there a Wegovy®-to-Foundayo® dosage chart?

No. Because Wegovy® and Foundayo® work differently in the body and are titrated on different schedules, there’s no official conversion between a Wegovy® dose and a Foundayo® starting point. Your provider will set your Foundayo® starting dose at 0.8 mg regardless of where you left off on Wegovy®.

How long will you wait between Wegovy® and Foundayo®?

There’s no FDA-recommended waiting period. Your provider will typically have you start Foundayo® around the time your next Wegovy® dose would have been due.

Switching from Wegovy® pill to Foundayo®: Side effects

Both medications share similar side effects, but how often they’re experienced varies. Nausea, vomiting, diarrhea, and constipation are still the most common. Here’s how the rates compare between the Wegovy® pill and Foundayo®:

• The two medications have very similar side effect profiles. Both commonly cause gastrointestinal symptoms—including nausea, vomiting, diarrhea, constipation, indigestion, and abdominal pain—especially when you’re first starting treatment or increasing your dose.
• Some side effects are reported more often with one medication than the other. At their highest studied doses, nausea (35% vs. 47%), vomiting (24% vs. 31%), and indigestion (13% vs. 18%) were reported less often with Foundayo® than with the Wegovy® pill. On the other hand, diarrhea (25% vs. 18%), constipation (24% vs. 20%), abdominal pain (14% vs. 9%), and fatigue (9% vs. 1%) were reported more frequently with Foundayo®.
• Most digestive side effects tend to improve over time. They’re usually mild to moderate and can be most noticeable while you’re increasing your dose. As your body adjusts to the medication, many people find these symptoms become less frequent or less intense.
• It’s hard to predict which medication you’ll tolerate better. Even though the overall side-effect patterns are similar, individual experiences can vary widely. Some people find Foundayo® easier to tolerate, while others do better on the Wegovy® pill. If one medication causes fewer side effects—or is simply easier to take consistently—it may end up being the better long-term fit, even if average weight loss differs between the two.
• Know when to contact your healthcare provider. Mild digestive symptoms are common, but severe, persistent, or worsening abdominal pain, repeated vomiting that prevents you from staying hydrated, or other concerning symptoms should be evaluated promptly.

Side effect	Wegovy® pill 25 mg	Foundayo® 17.2 mg
Nausea	47%	35%
Vomiting	31%	24%
Diarrhea	18%	25%
Constipation	20%	24%
Dyspepsia (indigestion)	18%	13%
Abdominal pain / upper abdominal pain	9%	14%
Headache	12%	9%
Fatigue	1%	9%

Will I have more side effects with Foundayo after switching from Wegovy?

Not necessarily. Everyone responds a little differently, and a few factors can influence how smoothly the transition goes.

• Your titration schedule. Even if you’re already taking the Wegovy® pill, your healthcare provider will typically start Foundayo® at its recommended starting dose and gradually increase it over time. This helps your body adjust and can reduce the risk of side effects.
• Your individual tolerance. Some people tolerate semaglutide better, while others find orforglipron easier on their stomach. There’s no way to predict exactly how you’ll respond until you make the switch.
• Your daily routine. Foundayo® can be taken with or without food and at any time of day, which some people find easier to stick with than the Wegovy® pill’s empty-stomach dosing requirements. Sticking to your dosing schedule, eating smaller meals if nausea occurs, and staying hydrated may also help minimize side effects.

Read more: 

• Wegovy® pill vs Foundayo®: Which one works best for weight loss?

Serious side effects: Any differences?

The serious warnings are very similar for both medications. That’s because they’re tied to how GLP-1 medications work as a class rather than to one specific drug. The reassuring news is that serious side effects are uncommon, and based on the available clinical trial data, the overall safety profiles of the Wegovy® pill and Foundayo® look broadly similar. Here’s how they compare:

• Boxed warning. Both medications carry a boxed warning about a possible risk of thyroid C-cell tumors based on animal studies. Neither should be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
• Gallbladder problems. Rapid weight loss can increase the risk of gallstones, regardless of which medication you’re taking. Gallstones and gallbladder inflammation have been reported with both semaglutide and orforglipron, although these events were uncommon in clinical trials.
• Pancreatitis. Pancreatitis was rare in clinical trials of both medications. Seek medical care right away if you develop severe, persistent abdominal pain that may spread to your back, especially if it’s accompanied by vomiting.
• Kidney problems. These are usually linked to dehydration caused by severe nausea, vomiting, or diarrhea. Staying well hydrated is especially important when starting treatment or increasing your dose.
• Serious allergic reactions. Although rare, serious hypersensitivity reactions have been reported with both medications.
• Low blood sugar (hypoglycemia). The risk is generally low unless you’re also taking insulin or a sulfonylurea, which can increase the chance of blood sugar dropping too low.

Will you lose more or less weight after switching from Wegovy® to Foundayo®?

If you’re thinking about switching medications, one of the biggest questions is whether it will affect your weight loss.

Based on the research available today, Foundayo® is associated with less average weight loss than either form of Wegovy®. But that doesn’t necessarily mean you’ll lose less weight if you switch. Clinical trial averages can’t predict how any one person will respond, and factors like side effects, cost, insurance coverage, and how consistently you’re able to stay on treatment all influence real-world results.

What the studies tell us

Both Wegovy® pills and Foundayo® can produce meaningful weight loss, but the available research suggests the Wegovy® pill leads to slightly greater weight loss on average.

It’s important to keep that difference in perspective. The medications haven’t been compared directly in a head-to-head trial, so these results come from separate studies. And while the averages differ by a few percentage points, the actual difference in pounds may be smaller than many people expect.

Here’s what the clinical trials found:

• Wegovy® pill: In the OASIS 4 trial, people taking the highest approved dose lost an average of 14% of their starting body weight over about 64 weeks.
• Foundayo®: In the ATTAIN-1 and ATTAIN-2 trials, people taking the highest approved dose lost an average of 11 to 12% of their starting body weight over 72 weeks.

To put that into perspective, imagine two people who each start at 200 pounds:

Medication	Average weight loss	Approximate pounds lost
Wegovy® pill	14%	28 pounds
Foundayo®	12%	24 pounds

That’s a difference of about 4 pounds for someone starting at 200 pounds. While that difference may matter to some people, it’s only one part of the decision. Factors like side effects, insurance coverage, cost, and whether you can stay on the medication long term can have just as much influence on your overall success.

How long does it take to see results?

Weight loss with both medications tends to build gradually rather than happening all at once. Many people notice their appetite changes within the first few weeks, while meaningful weight loss accumulates over several months as the dose increases.

At their highest approved doses, average weight loss in the clinical trials looked like this:

Time on treatment	Wegovy® pill	Foundayo®
After 3 months	6%	7%
After 6 months	11%	10%
After 1 year and beyond	14%	11–12%

These numbers provide a general benchmark—not a prediction of what you’ll lose. Your starting weight, genetics, nutrition, physical activity, sleep, other health conditions, and how consistently you’re able to stay on treatment all influence your results. For many people, the medication that’s easiest to tolerate and stick with is ultimately the one that delivers the best long-term outcome.

Can you continue losing weight after switching?

Yes, though given the lower average results associated with Foundayo®, some people who switch from a higher Wegovy® dose may see their weight loss level off or partially reverse if their Foundayo® dose isn’t equivalent in effect. Your provider can help set a realistic target based on the dose you’re likely to reach.

What if you’re switching for maintenance?

The strongest maintenance evidence right now is for semaglutide. In the STEP 4 trial, people who kept taking weekly Wegovy® injections held onto their weight loss, while those who stopped treatment regained much of it. Because Foundayo® is newer, long-term maintenance data is more limited — something to raise with your provider if long-term weight maintenance is your priority.

Switching from Wegovy® to Foundayo®: Cost and insurance considerations

Cost is one of the more common reasons people consider this switch, but whether Foundayo® actually saves you money depends on your insurance, your eligibility for manufacturer savings, and the dose you land on.

• With insurance: Both medications may be available for as little as $25 per month for eligible people with commercial insurance, and both participate in the Medicare GLP-1 Bridge Program for eligible beneficiaries. The biggest difference is often whether your health plan covers one medication but not the other.
• Without insurance: At the lower end of the dose range, Foundayo® and the Wegovy® pill cost about the same. Once you’re at a maintenance dose, the Wegovy® pill pulls ahead as the better deal — its $299 ceiling is $50 less than Foundayo®’s $349 highest dose. 

Pricing	Foundayo® (orforglipron)	Wegovy® pill (semaglutide)
With insurance	Varies by plan. With eligible commercial insurance and the Foundayo® Savings Card, you may pay as little as $25/month. Eligible Medicare beneficiaries can pay $50/month through the Medicare GLP-1 Bridge Program (July 2026–December 2027). Medicaid coverage varies by state.	Varies by plan. With eligible commercial insurance and the Wegovy® Savings Offer, you may pay as little as $25/month. Eligible Medicare beneficiaries can pay $50/month through the Medicare GLP-1 Bridge Program (July 2026–December 2027). Medicaid coverage varies by state.
Without insurance	Paying cash through LillyDirect: • 0.8 mg: $149/month • 2.5 mg: $199/month • 5.5 mg, 9 mg, 14.5 mg: $299/month* • 17.2 mg: $349/month	Paying cash through NovoCare Pharmacy: • 1.5 mg, 4 mg: $149/month • 9 mg, 25 mg: $299/month

Read more: 

• Wegovy® pill cost, with and without insurance
• Does Medicare cover Wegovy®?
• Is Foundayo® covered by Medicare?

Will insurance cover clinician appointments for the switch?

Maybe, and switching almost always involves a few clinician visits and paperwork. A few things to plan for:

• Prior authorization. Changing medications usually means a new prior authorization request for your plan, if needed, which can take a few days to a few weeks. 
• Formularies and step therapy. Some plans require you to try other options before they’ll cover Foundayo®, or vice versa. Formulary changes are one of the more common reasons providers recommend switching in the first place.
• Lab testing: Not required for everyone, but your provider may order blood work depending on your history or any side effects you develop.
• Pharmacy networks. Your new coverage may route you to a different preferred or specialty pharmacy, and not every pharmacy stocks every product or participates in every savings program.
• Medicare specifics. Expect an appointment to review your Wegovy® history, introduce Foundayo® at the 0.8mg starting dose, and offer follow-up visits as your dose increases.

Frequently asked questions about switching from Wegovy® to Foundayo®

Can I switch directly from Wegovy® to Foundayo®?

There’s no FDA-recommended waiting period. Your provider will typically time your first Foundayo® dose around when your next Wegovy® dose would have been due.

Is there a Wegovy®-to-Foundayo® dosage chart?

No. The two drugs have different active ingredients and titration schedules, so there’s no official dose-conversion chart. Your provider sets your starting Foundayo® dose at 0.8 mg regardless of your prior Wegovy® dose.

Will Foundayo® work if Wegovy® worked for me?

It’s possible, though the average results run lower for Foundayo® across the trial data available so far. Your provider can help you set expectations based on how you responded to Wegovy® and your overall health picture.

Will I lose more or less weight after switching?

Likely less, on average — Foundayo®’s trial results (about 11–12% at its highest dose) are lower than either Wegovy® pill (13.6–16.6%) or Wegovy® injection (up to 18.7%) results. Individual responses vary.

Is Foundayo® cheaper than the Wegovy® pill?

It depends on the dose. At the low end, Foundayo® and the Wegovy® pill cost the same. At the highest dosing range, though, the Wegovy® pill is the cheapest of the three at $299/month, compared with $349 for Foundayo®.

Does Foundayo® require the same timing rules as the Wegovy® pill?

No. The Wegovy® pill needs to be taken on an empty stomach with only a small amount of water, then followed by a 30-minute wait before eating, drinking, or taking other oral medications. Foundayo® can be taken at any time of day, with or without food or water.

What should I ask my doctor before switching?

• How long should I wait between my last Wegovy® dose and my first Foundayo® dose?
• What side effects should I watch for, and when should I call if they become concerning?
• Given that Foundayo®’s average weight loss is lower in trials, what’s a realistic goal for me?

The bottom line: Switching from Wegovy® to Foundayo® is  personalized 

People switch from Wegovy® to Foundayo® mainly because of insurance coverage, cost, or the convenience of a pill without food and water restrictions—not because it’s associated with greater weight loss. In clinical trials, Foundayo® produced lower average weight loss than both the Wegovy® pill and the Wegovy® injection.

But average weight loss is only part of the picture. The medication that’s most effective for you is often the one you can tolerate, afford, and take consistently over time. If fewer dosing restrictions or milder side effects help you stay on treatment, that may outweigh differences in average weight loss seen in clinical trials.

Because there’s no FDA-approved dose-conversion chart, your healthcare provider will have you begin Foundayo® at 0.8 mg and gradually increase the dose over several months.

Ultimately, the goal isn’t simply to switch medications—it’s to find a treatment you can stick with long enough to support lasting health. Your healthcare provider can help you weigh the potential benefits and tradeoffs based on your medical history, goals, side effects, and insurance coverage. Pairing whichever medication you use with balanced nutrition, regular physical activity, and sustainable behavior changes will have an important impact on your long-term success.

If you qualify, the clinicians at Noom Med can help you determine whether switching from Wegovy® to Foundayo® makes sense for your situation and guide you through the process safely, combining medical care with psychology-based coaching and ongoing support.